David Wheeler
Pulmonary Disease · Philadelphia, PANPI 1386906808
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,000 of the $2,062 with a category attached, or 97.0%. Every reported general payment came from a single manufacturer, Pfizer.
Across 3 payments — averaging $687.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
Across 615 payments — averaging $12,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$6.3M
- Pfizer$1.4M
- GSK$80K
- Teva Pharmaceuticals USA, Inc.$19K
What the payments were for
- Consulting fees$2,00097%
- Travel & lodging$291%
- Food & beverage$342%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $2,062 |
How this compares
$2,062 in reported general payments places this provider in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.